Susineridine
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Susineridine (INN; developmental code name YZJ-4729) is an atypical μ-opioid receptor (MOR) agonist and opioid analgesic which is under development for the treatment of postoperative pain.[1][4][2][3] It is given intravenously.[1]
| |
| Clinical data | |
|---|---|
| Other names | YZJ-4729; YZJ4729 |
| Routes of administration | Intravenous[1][2] |
| Drug class | μ-Opioid receptor biased partial agonist; Analgesic |
| Pharmacokinetic data | |
| Elimination half-life | 0.9–2.5 hours[2][3] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C25H36N4O |
| Molar mass | 408.590 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
The drug acts as a selective biased partial agonist of the MOR, with functional selectivity for activation of G protein signaling over β-arrestin2 recruitment.[2][3] Its mechanism of action and pharmacological activity are said to be similar to those of oliceridine.[2][3] However, in-vitro findings suggest that susineridine may have a greater degree of G protein bias than oliceridine.[2] The drug produces analgesic effects in multiple animal models of pain and produces less respiratory depression than morphine or oliceridine.[2][3] The pharmacokinetics of susineridine in humans have been studied.[2][3]
Susineridine was patented[5] and first described in the scientific literature in 2023.[2][3] It is under development by Shanghai Haiyan Pharmaceutical Technology in China.[1][4] As of May 2025, the drug is in phase 3 clinical trials for postoperative pain.[1][4]